İsMet Bulut
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
İsMet Bulut has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Zeynep Yegin Katran
Department of Allergy and Immunology, University of Health Sciences, Süreyyapaşa Training and Research Hospital
10 shared publications - Özge Argın
Department of Allergy and Immunology, Süreyyapasa Training and Research Hospital, University of Health Sciences, Istanbul, Turkey
4 shared publications - Aylin Babalik
Department of Chest Diseases, University of Health Sciences, Süreyyapaşa Training and Research Hospital, Istanbul, Turkey
3 shared publications - Cihan Orcen
Clinic of Allergy and Immunology, University of Health Sciences, Kocaeli Derince Training and Research Hospital
3 shared publications Dilek Yavuz
Univ Hlth Sci, Sureyyapasa Training & Res Hosp, Dept Allergy & Immunol, Istanbul, Turkiye
2 shared publications- Metin Keren
Süreyyapaşa Chest Diseases and Thoracic Surgery Training and Research Hospital Clinic of Immunology and Allergy University of Health Sciences Türkiye İstanbul Türkiye
2 shared publications
Latest Publications
- 1 July 2026
- Published by Codon Publications in Allergologia et Immunopathologia
- Vol. 54 (4) , 81-86
Is local anaesthetic drug allergy really common? A 10-year single-centre retrospective analysis
Background: True allergic reactions to local anaesthetic (LA) agents are extremely rare, yet patients are frequently referred to allergy clinics with a history suggestive of LA hypersensitivity. This study aimed to evaluate the clinical characteristics, risk factors, and diagnostic outcomes of patients referred with suspected LA hypersensitivity. Methods: We retrospectively reviewed all patients evaluated for suspected LA hypersensitivity between 2014 and 2025 in a tertiary allergy centre. Demographic, clinical and laboratory data, including comorbid allergic diseases, total IgE, eosinophil count and serum tryptase levels, were analysed. All patients underwent standardised skin testing and, when indicated, subcutaneous provocation testing with preservative-free LA agents. Logistic regression was used to identify independent predictors of LA hypersensitivity history. Results: A total of 149 patients (mean age 46.7 ± 13.9 years; 83.9% females) were included. No confirmed cases of IgE-mediated LA hypersensitivity were detected. The most common comorbidities were atopy (50.0%), asthma (24.3%) and allergic rhinitis (34.4%). True LA hypersensitivity was not confirmed in any case; however, at least one safe agent was identified in 83.2% of patients, most frequently lidocaine (63.8%). In multivariate analysis, age was the only independent predictor of reporting LA hypersensitivity (Odds ratio (OR) = 1.02; P = 0.039). Atopy (OR = 0.36; P < 0.001) and asthma (OR = 0.28; P < 0.001) were found to be negative predictors, possibly reflecting referral bias. Multiple drug hypersensitivity was observed in 1.4% of patients, but was not an independent risk factor. Conclusions: True local anaesthetic hypersensitivity is exceedingly rare. A detailed history combined with appropriate skin and provocation testing prevents unnecessary avoidance of safe agents. Referral bias and overestimation of risk remain common in clinical practice.
- 1 July 2026
- Published by Codon Publications in Allergologia et Immunopathologia
- Vol. 54 (4) , 81-86
Is local anaesthetic drug allergy really common? A 10-year single-centre retrospective analysis
Background: True allergic reactions to local anaesthetic (LA) agents are extremely rare, yet patients are frequently referred to allergy clinics with a history suggestive of LA hypersensitivity. This study aimed to evaluate the clinical characteristics, risk factors, and diagnostic outcomes of patients referred with suspected LA hypersensitivity. Methods: We retrospectively reviewed all patients evaluated for suspected LA hypersensitivity between 2014 and 2025 in a tertiary allergy centre. Demographic, clinical and laboratory data, including comorbid allergic diseases, total IgE, eosinophil count and serum tryptase levels, were analysed. All patients underwent standardised skin testing and, when indicated, subcutaneous provocation testing with preservative-free LA agents. Logistic regression was used to identify independent predictors of LA hypersensitivity history. Results: A total of 149 patients (mean age 46.7 ± 13.9 years; 83.9% females) were included. No confirmed cases of IgE-mediated LA hypersensitivity were detected. The most common comorbidities were atopy (50.0%), asthma (24.3%) and allergic rhinitis (34.4%). True LA hypersensitivity was not confirmed in any case; however, at least one safe agent was identified in 83.2% of patients, most frequently lidocaine (63.8%). In multivariate analysis, age was the only independent predictor of reporting LA hypersensitivity (Odds ratio (OR) = 1.02; P = 0.039). Atopy (OR = 0.36; P < 0.001) and asthma (OR = 0.28; P < 0.001) were found to be negative predictors, possibly reflecting referral bias. Multiple drug hypersensitivity was observed in 1.4% of patients, but was not an independent risk factor. Conclusions: True local anaesthetic hypersensitivity is exceedingly rare. A detailed history combined with appropriate skin and provocation testing prevents unnecessary avoidance of safe agents. Referral bias and overestimation of risk remain common in clinical practice.
- Open Access
- 30 June 2026
- Published by Cukurova Anestezi ve Cerrahi Bilimler Dergisi in Cukurova Anestezi ve Cerrahi Bilimler Dergisi
- Vol. 9 (2) , 421-426
Psychiatric Burden in Adult Patients with Common Variable Immunodeficiency: A Single-Center Cross-Sectional Study
Aim: Common Variable Immunodeficiency (CVID) is characterized by recurrent infections and chronic complications. While the infectious burden of CVID has been extensively studied, psychiatric comorbidities remain underrecognized. This study aimed to evaluate psychiatric symptom burden and associated factors in adult CVID patients receiving immunoglobulin replacement therapy.Methods: Sixteen adult patients with CVID were included in this cross-sectional study. Demographic and clinical data were collected retrospectively. Anxiety and depressive symptoms were assessed using the Hospital Anxiety and Depression Scale (HADS). Psychiatric diagnoses were classified according to DSM-5 criteria. Infection frequency before and after immunoglobulin replacement therapy was compared using the Wilcoxon signed-rank test. Associations between clinical variables and HADS scores were analyzed using nonparametric tests.Results: The mean age of the patients was 43.2 ± 14.9 years, and 50% were female. Immunoglobulin replacement therapy was associated with significant reductions in annual pneumonia (p=0.001), sinusitis (p=0.003), and antibiotic use (p=0.001). Clinically significant anxiety (HADS-A ≥11) was observed in 50% of patients, and depressive symptoms (HADS-D ≥11) in 56.3%. Eight patients (50%) met DSM-5 criteria for at least one psychiatric disorder. Anxiety and depressive scores were strongly correlated (ρ=0.939, p
- 30 June 2026
- Published by Cukurova Anestezi ve Cerrahi Bilimler Dergisi in Cukurova Anestezi ve Cerrahi Bilimler Dergisi
- Vol. 9 (2) , 421-426
Open AccessPsychiatric Burden in Adult Patients with Common Variable Immunodeficiency: A Single-Center Cross-Sectional Study
Aim: Common Variable Immunodeficiency (CVID) is characterized by recurrent infections and chronic complications. While the infectious burden of CVID has been extensively studied, psychiatric comorbidities remain underrecognized. This study aimed to evaluate psychiatric symptom burden and associated factors in adult CVID patients receiving immunoglobulin replacement therapy.Methods: Sixteen adult patients with CVID were included in this cross-sectional study. Demographic and clinical data were collected retrospectively. Anxiety and depressive symptoms were assessed using the Hospital Anxiety and Depression Scale (HADS). Psychiatric diagnoses were classified according to DSM-5 criteria. Infection frequency before and after immunoglobulin replacement therapy was compared using the Wilcoxon signed-rank test. Associations between clinical variables and HADS scores were analyzed using nonparametric tests.Results: The mean age of the patients was 43.2 ± 14.9 years, and 50% were female. Immunoglobulin replacement therapy was associated with significant reductions in annual pneumonia (p=0.001), sinusitis (p=0.003), and antibiotic use (p=0.001). Clinically significant anxiety (HADS-A ≥11) was observed in 50% of patients, and depressive symptoms (HADS-D ≥11) in 56.3%. Eight patients (50%) met DSM-5 criteria for at least one psychiatric disorder. Anxiety and depressive scores were strongly correlated (ρ=0.939, p
- 17 March 2026
- Published by Cukurova Anestezi ve Cerrahi Bilimler Dergisi in Cukurova Anestezi ve Cerrahi Bilimler Dergisi
- Vol. 9 (1) , 40-47
Real-Life Outcomes of Oral Provocation Testing with Alternative NSAIDs in NSAID Hypersensitivity
Background: Nonsteroidal anti-inflammatory drugs (NSAIDs) are among the most common causes of drug hypersensitivity reactions. Identifying safe alternative NSAIDs through oral provocation testing (OPT) is essential for clinical management. The 2025 World Allergy Organization (WAO) classification introduced updated phenotypes, highlighting the need for real-life data on tolerated alternative agents.Materials and methods:This retrospective study included 824 adults evaluated for suspected NSAID hypersensitivity between January 2020 and September 2025. Patients were reclassified according to the 2025 WAO criteria. Demographic characteristics, comorbid allergic diseases, culprit drugs, laboratory parameters, and outcomes of OPT with alternative NSAIDs were analyzed.Results:The mean age was 44.7 ± 13.2 years, and 65.5% of patients were female. According to the 2025 WAO classification, 48.8% had NSAID-exacerbated cutaneous disease (NECD), 32.2% NSAID-induced urticaria/angioedema (NIUA), and 11.2% single NSAID-induced urticaria/angioedema/anaphylaxis (SNIUAA). Among 704 patients undergoing OPT, tolerance rates were high for meloxicam (96%), nimesulide (97%), and celecoxib (98.6%). The distribution of asthma, rhinitis, urticaria/angioedema, chronic sinusitis, and nasal polyps differed significantly among WAO phenotypes (p < 0.05), whereas tolerance to alternative NSAIDs did not differ between groups (p > 0.05).Conclusion:Meloxicam, nimesulide, and celecoxib are well tolerated in most patients with NSAID hypersensitivity. The 2025 WAO classification improves phenotypic stratification, while OPT remains a reliable method for identifying safe alternative NSAIDs in real-life practice.
- 17 March 2026
- Published by Cukurova Anestezi ve Cerrahi Bilimler Dergisi in Cukurova Anestezi ve Cerrahi Bilimler Dergisi
- Vol. 9 (1) , 40-47
Real-Life Outcomes of Oral Provocation Testing with Alternative NSAIDs in NSAID Hypersensitivity
Background: Nonsteroidal anti-inflammatory drugs (NSAIDs) are among the most common causes of drug hypersensitivity reactions. Identifying safe alternative NSAIDs through oral provocation testing (OPT) is essential for clinical management. The 2025 World Allergy Organization (WAO) classification introduced updated phenotypes, highlighting the need for real-life data on tolerated alternative agents.Materials and methods:This retrospective study included 824 adults evaluated for suspected NSAID hypersensitivity between January 2020 and September 2025. Patients were reclassified according to the 2025 WAO criteria. Demographic characteristics, comorbid allergic diseases, culprit drugs, laboratory parameters, and outcomes of OPT with alternative NSAIDs were analyzed.Results:The mean age was 44.7 ± 13.2 years, and 65.5% of patients were female. According to the 2025 WAO classification, 48.8% had NSAID-exacerbated cutaneous disease (NECD), 32.2% NSAID-induced urticaria/angioedema (NIUA), and 11.2% single NSAID-induced urticaria/angioedema/anaphylaxis (SNIUAA). Among 704 patients undergoing OPT, tolerance rates were high for meloxicam (96%), nimesulide (97%), and celecoxib (98.6%). The distribution of asthma, rhinitis, urticaria/angioedema, chronic sinusitis, and nasal polyps differed significantly among WAO phenotypes (p < 0.05), whereas tolerance to alternative NSAIDs did not differ between groups (p > 0.05).Conclusion:Meloxicam, nimesulide, and celecoxib are well tolerated in most patients with NSAID hypersensitivity. The 2025 WAO classification improves phenotypic stratification, while OPT remains a reliable method for identifying safe alternative NSAIDs in real-life practice.
- 17 March 2026
- Published by Cukurova Anestezi ve Cerrahi Bilimler Dergisi in Cukurova Anestezi ve Cerrahi Bilimler Dergisi
- Vol. 9 (1) , 150-158
Severe Asthma, Allergen Sensitization, and Chronic Rhinosinusitis: A 10-Year Real-Life Cohort Study
Background: Severe asthma frequently coexists with allergen sensitization and chronic rhinosinusitis (CRS), both of which contribute to disease burden. Real-life data describing sensitization patterns and CRS characteristics in severe asthma remain limited.Objective: To evaluate allergen sensitization profiles, clinical and CT-confirmed CRS, and nasal polyp characteristics in a real-life cohort of patients with severe asthma.Methods: This retrospective study included adult patients with severe asthma followed over a 10-year period. Demographic characteristics, asthma-related features, sensitization patterns, sinonasal assessments, nasal polyp scores, and laboratory parameters were analyzed. Results: A total of 160 patients were included. Atopy was present in 71.9% of cases and was significantly less frequent in patients treated with benralizumab compared with other biologic therapies (p < 0.001). Clinical CRS was detected in 60.1%, while CT-confirmed CRS was present in 70.7%. Monosensitized patients had significantly lower rates of both clinical and CT-confirmed CRS (p = 0.048 and p = 0.002, respectively). Nasal polyps were identified in 19.3% of patients, with a recurrence rate of 30.9%. Dermatophagoides farinae and Dermatophagoides pteronyssinus were the most common sensitizations.Conclusion: Allergen sensitization and CRS/CRSwNP are highly prevalent in severe asthma and shape the clinical phenotype of the disease. Comprehensive evaluation of upper-airway involvement and sensitization is essential in the management of severe asthma.
- 17 March 2026
- Published by Cukurova Anestezi ve Cerrahi Bilimler Dergisi in Cukurova Anestezi ve Cerrahi Bilimler Dergisi
- Vol. 9 (1) , 150-158
Severe Asthma, Allergen Sensitization, and Chronic Rhinosinusitis: A 10-Year Real-Life Cohort Study
Background: Severe asthma frequently coexists with allergen sensitization and chronic rhinosinusitis (CRS), both of which contribute to disease burden. Real-life data describing sensitization patterns and CRS characteristics in severe asthma remain limited.Objective: To evaluate allergen sensitization profiles, clinical and CT-confirmed CRS, and nasal polyp characteristics in a real-life cohort of patients with severe asthma.Methods: This retrospective study included adult patients with severe asthma followed over a 10-year period. Demographic characteristics, asthma-related features, sensitization patterns, sinonasal assessments, nasal polyp scores, and laboratory parameters were analyzed. Results: A total of 160 patients were included. Atopy was present in 71.9% of cases and was significantly less frequent in patients treated with benralizumab compared with other biologic therapies (p < 0.001). Clinical CRS was detected in 60.1%, while CT-confirmed CRS was present in 70.7%. Monosensitized patients had significantly lower rates of both clinical and CT-confirmed CRS (p = 0.048 and p = 0.002, respectively). Nasal polyps were identified in 19.3% of patients, with a recurrence rate of 30.9%. Dermatophagoides farinae and Dermatophagoides pteronyssinus were the most common sensitizations.Conclusion: Allergen sensitization and CRS/CRSwNP are highly prevalent in severe asthma and shape the clinical phenotype of the disease. Comprehensive evaluation of upper-airway involvement and sensitization is essential in the management of severe asthma.
- Open Access
- 1 July 2025
- Published by Codon Publications in Allergologia et Immunopathologia
- Vol. 52 (4) , 134-137
A rare case of type IV hypersensitivity: Prilocaine allergy
Allergic reactions caused by local anesthetics are quite rare and these reactions often manifest as Type I (immediate-type) hypersensitivity; however, Type IV (delayed-type) hypersensitivity reactions also hold clinical significance. Type IV reactions are generally T-lymphocyte mediated and symptoms appear hours or days after antigen exposure. In this case report, a rare Type IV hypersensitivity reaction to prilocaine, an amide-type local anesthetic, is described. The patient presented to our center due to the delayed-onset skin lesions that developed after previous surgical procedures and was evaluated through comprehensive allergy testing. A positive delayed-type reaction to prilocaine was observed in the intradermal and patch tests; however, no reaction was detected in the provocation test performed with mepivacaine. This highlights the importance of careful selection of local anesthetics and consideration of Type IV hypersensitivity. Sharing such cases contributes to increased clinical awareness.
- 1 July 2025
- Published by Codon Publications in Allergologia et Immunopathologia
- Vol. 52 (4) , 134-137
Open AccessA rare case of type IV hypersensitivity: Prilocaine allergy
Allergic reactions caused by local anesthetics are quite rare and these reactions often manifest as Type I (immediate-type) hypersensitivity; however, Type IV (delayed-type) hypersensitivity reactions also hold clinical significance. Type IV reactions are generally T-lymphocyte mediated and symptoms appear hours or days after antigen exposure. In this case report, a rare Type IV hypersensitivity reaction to prilocaine, an amide-type local anesthetic, is described. The patient presented to our center due to the delayed-onset skin lesions that developed after previous surgical procedures and was evaluated through comprehensive allergy testing. A positive delayed-type reaction to prilocaine was observed in the intradermal and patch tests; however, no reaction was detected in the provocation test performed with mepivacaine. This highlights the importance of careful selection of local anesthetics and consideration of Type IV hypersensitivity. Sharing such cases contributes to increased clinical awareness.
- Open Access
- 11 September 2024
- Published by Elsevier in World Allergy Organization Journal
- Vol. 17 (9) , 100962
Anaphylaxis in a country where Asia and Europe meet: Evaluation according to World Allergy Organization (WAO) and European Academy of Allergy and Clinical Immunology (EAACI) diagnostic criteria
- 11 September 2024
- Published by Elsevier in World Allergy Organization Journal
- Vol. 17 (9) , 100962
Open AccessAnaphylaxis in a country where Asia and Europe meet: Evaluation according to World Allergy Organization (WAO) and European Academy of Allergy and Clinical Immunology (EAACI) diagnostic criteria
- Open Access
- 13 June 2023
- Published by Bilimsel Tip Publishing House in Tuberk Toraks
- Vol. 71 (2) , 148-155
Effectiveness of mepolizumab in patients with severe eosinophilic asthma: In a real life study
We analyzed the effects of mepolizumab treatment on symptoms, asthma attacks, pulmonary function test parameters peripheral blood eosinophil level, and percentage in patients with severe eosinophilic asthma receiving mepolizumab treatment as the baseline, sixth and twelfthmonth data. The medical records of patients diagnosed with severe eosinophilic asthma and treated with mepolizumab at our clinic were retrospectively reviewed for the period between January 2018 and December 2021. Demographic data of the patients, duration of asthma disease, comorbidities such as a nasal polyp, eosinophilic granulomatous polyangiitis, and nonsteroidal anti-inflammatory drug exacerbated respiratory disease were investigated. A comparison was made of various factors before initiating mepolizumab treatment, as well as at the sixth and twelfth month after treatment initiation. These factors include asthma control test scores, frequency of asthma attacks (including emergency admissions, hospitalizations, and intensive care admissions), peripheral blood eosinophil levels and percentages, and pulmonary function test parameters. Clinic and laboratory parameters that provide a prediction of being a responder and super responder were evaluated. A total of 21 patients were included in the study. Their mean age was 50.7 ± 11.9 years, and four (19%) were males. The mean duration of asthma diagnosis was 17.5 ±13.7 years. 14 patients (66.7%) were atopic. 4 patients (19%) had nasal polyps and four patients (19%) had NERD. Before mepolizumab, 13 (61.9%) patients had received omalizumab. The duration of receiving mepolizumab treatment was 29.2 ± 9.9 months. A statistically significant decrease was observed in both the number and percentage of eosinophils at months six and 12 (p<0.01). There was a statistically significant increase in FEV1 values both as a percentage and in milliliters at month 12. There was an increase in both percentage and milliliters in FEF25-75 values, but this increase did not reach statistical significance. There was a decrease in service admissions, intensive care admissions, and emergency admissions due to asthma exacerbations. Out of 21 patients, 11 (52.4%) were classified as responders, while 10 (47.6%) were classified as super responders. Although the number of patients in our study was limited, mepolizumab improved symptom scores in severe eosinophilic asthma, reduced the number of attacks, and improved pulmonary function test values.
- 13 June 2023
- Published by Bilimsel Tip Publishing House in Tuberk Toraks
- Vol. 71 (2) , 148-155
Open AccessEffectiveness of mepolizumab in patients with severe eosinophilic asthma: In a real life study
We analyzed the effects of mepolizumab treatment on symptoms, asthma attacks, pulmonary function test parameters peripheral blood eosinophil level, and percentage in patients with severe eosinophilic asthma receiving mepolizumab treatment as the baseline, sixth and twelfthmonth data. The medical records of patients diagnosed with severe eosinophilic asthma and treated with mepolizumab at our clinic were retrospectively reviewed for the period between January 2018 and December 2021. Demographic data of the patients, duration of asthma disease, comorbidities such as a nasal polyp, eosinophilic granulomatous polyangiitis, and nonsteroidal anti-inflammatory drug exacerbated respiratory disease were investigated. A comparison was made of various factors before initiating mepolizumab treatment, as well as at the sixth and twelfth month after treatment initiation. These factors include asthma control test scores, frequency of asthma attacks (including emergency admissions, hospitalizations, and intensive care admissions), peripheral blood eosinophil levels and percentages, and pulmonary function test parameters. Clinic and laboratory parameters that provide a prediction of being a responder and super responder were evaluated. A total of 21 patients were included in the study. Their mean age was 50.7 ± 11.9 years, and four (19%) were males. The mean duration of asthma diagnosis was 17.5 ±13.7 years. 14 patients (66.7%) were atopic. 4 patients (19%) had nasal polyps and four patients (19%) had NERD. Before mepolizumab, 13 (61.9%) patients had received omalizumab. The duration of receiving mepolizumab treatment was 29.2 ± 9.9 months. A statistically significant decrease was observed in both the number and percentage of eosinophils at months six and 12 (p<0.01). There was a statistically significant increase in FEV1 values both as a percentage and in milliliters at month 12. There was an increase in both percentage and milliliters in FEF25-75 values, but this increase did not reach statistical significance. There was a decrease in service admissions, intensive care admissions, and emergency admissions due to asthma exacerbations. Out of 21 patients, 11 (52.4%) were classified as responders, while 10 (47.6%) were classified as super responders. Although the number of patients in our study was limited, mepolizumab improved symptom scores in severe eosinophilic asthma, reduced the number of attacks, and improved pulmonary function test values.
- Open Access
- 20 May 2023
- Published by Elsevier in World Allergy Organization Journal
- Vol. 16 (5) , 100778
Drug hypersensitivity in drug-resistant tuberculosis
- 20 May 2023
- Published by Elsevier in World Allergy Organization Journal
- Vol. 16 (5) , 100778
Open AccessDrug hypersensitivity in drug-resistant tuberculosis
- Open Access
- 21 November 2022
- Published by Springer Nature in Allergy, Asthma & Clinical Immunology
- Vol. 18 (1) , 1-8
Management of type 1 immediate hypersensitivity reactions to antituberculosis drug: succesful desensitization
Objective: In this study, it was aimed to investigate the prevalence of type 1 hypersensitivity reaction under tuberculosis treatment and the management of hypersensitivity. Methods: The study is a case series. All of the patients who were hospitalized between 01.02.2015–01.05.2021 were examined. All patients who developed a drug-induced type 1 immediate hypersensitivity reaction were included. Antituberculosis drugs were given with the protocol made by Buhari et al. However, unlike what is stated in the protocol, pyrazinamide was given last during the administration of the drugs. Results: 2677 patients received inpatient tuberculosis treatment; type 1 immediate hypersensitivity reactions were seen in 94 (3.5%) patients. Due to missing data in the file, 81 patients were included in the study. 44 (54.3%) of the cases were women; mean age (mean ± SD) 50.7 ± 17.69 years; 76 (93.8%) of them are citizens of the Republic of Turkey; 58 (71.6%) of them were diagnosed bacteriologically; 65 (80.2%) of them were pulmonary tuberculosis. The most common skin finding was urticaria in 49 (60.5%). The drug responsible for the most common reaction was pyrazinamide. In 49 (60.5%) cases, drugs were given by desensitization and it was successful. The duration of treatment was 7.91 ± 2.5 months (6–18 months). When evaluated in terms of treatment results, 68 (84%) patients successfully completed the treatment. Conclusion: Our study is the largest series of patients who developed type 1 immediate hypersensitivity reaction while receiving antituberculosis treatment. A practical, easy desensitization scheme has been shared.
- 21 November 2022
- Published by Springer Nature in Allergy, Asthma & Clinical Immunology
- Vol. 18 (1) , 1-8
Open AccessManagement of type 1 immediate hypersensitivity reactions to antituberculosis drug: succesful desensitization
Objective: In this study, it was aimed to investigate the prevalence of type 1 hypersensitivity reaction under tuberculosis treatment and the management of hypersensitivity. Methods: The study is a case series. All of the patients who were hospitalized between 01.02.2015–01.05.2021 were examined. All patients who developed a drug-induced type 1 immediate hypersensitivity reaction were included. Antituberculosis drugs were given with the protocol made by Buhari et al. However, unlike what is stated in the protocol, pyrazinamide was given last during the administration of the drugs. Results: 2677 patients received inpatient tuberculosis treatment; type 1 immediate hypersensitivity reactions were seen in 94 (3.5%) patients. Due to missing data in the file, 81 patients were included in the study. 44 (54.3%) of the cases were women; mean age (mean ± SD) 50.7 ± 17.69 years; 76 (93.8%) of them are citizens of the Republic of Turkey; 58 (71.6%) of them were diagnosed bacteriologically; 65 (80.2%) of them were pulmonary tuberculosis. The most common skin finding was urticaria in 49 (60.5%). The drug responsible for the most common reaction was pyrazinamide. In 49 (60.5%) cases, drugs were given by desensitization and it was successful. The duration of treatment was 7.91 ± 2.5 months (6–18 months). When evaluated in terms of treatment results, 68 (84%) patients successfully completed the treatment. Conclusion: Our study is the largest series of patients who developed type 1 immediate hypersensitivity reaction while receiving antituberculosis treatment. A practical, easy desensitization scheme has been shared.
- Open Access
- 1 July 2022
- Published by Springer Nature in Research Square
Management of type 1 hypersensitivity reactions to antituberculosis drug: Succesful Desensitization
Objective: Type 1 hypersensitivity reaction includes reactions such as dry itching, rash, urticaria, angioedema, and anaphylaxis that usually occur within the first hour after taking the drug. In this study, it was aimed to investigate the prevalence of type 1 hypersensitivity reaction under treatment and treatment management in tuberculosis patients.Methods: The study is a case series; All of the patients who were hospitalized between 01.02.2015- 01.05.2021 were examined. All patients who developed a drug-induced type 1 hypersensitivity reaction were included. Antituberculosis drugs were given with the protocol made by Buhari et al. However, unlike what is stated in the protocol, pyrazinamide was given last during the administration of the drugs.Results: 2677 patients received inpatient tuberculosis treatment; type 1 hypersensitivity reactions were seen in 94 (3.5%) patients. Due to missing data in the file, 81 patients were included in the study. 44 (54.3%) of the cases were women; mean age (mean ± SD) 50.7 ± 17.69 years; 76 (93.8%) of them are citizens of the Republic of Turkey; 58 (71.6%) of them were diagnosed bacteriologically; 65 (80.2%) of them were pulmonary tuberculosis. The most common skin finding was urticaria in 49 (60.5%). The drug responsible for the most common reaction was pyrazinamide. In 49 (60.5%) cases, drugs were given by desensitization and it was successful. The duration of treatment was 7.91 ± 2.5 months (6-18 months). When evaluated in terms of treatment results, 68 (84%) patients successfully completed the treatment.Conclusion: Our study is the largest series of patients in which the demographic and clinical characteristics of type 1 IgE-mediated hypersensitivity developed under antituberculosis treatment were examined. An applicable, understandable and successful diagnostic process roadmap and desensitization scheme that can be used in this situation are presented.
- 1 July 2022
- Published by Springer Nature in Research Square
Open AccessManagement of type 1 hypersensitivity reactions to antituberculosis drug: Succesful Desensitization
Objective: Type 1 hypersensitivity reaction includes reactions such as dry itching, rash, urticaria, angioedema, and anaphylaxis that usually occur within the first hour after taking the drug. In this study, it was aimed to investigate the prevalence of type 1 hypersensitivity reaction under treatment and treatment management in tuberculosis patients.Methods: The study is a case series; All of the patients who were hospitalized between 01.02.2015- 01.05.2021 were examined. All patients who developed a drug-induced type 1 hypersensitivity reaction were included. Antituberculosis drugs were given with the protocol made by Buhari et al. However, unlike what is stated in the protocol, pyrazinamide was given last during the administration of the drugs.Results: 2677 patients received inpatient tuberculosis treatment; type 1 hypersensitivity reactions were seen in 94 (3.5%) patients. Due to missing data in the file, 81 patients were included in the study. 44 (54.3%) of the cases were women; mean age (mean ± SD) 50.7 ± 17.69 years; 76 (93.8%) of them are citizens of the Republic of Turkey; 58 (71.6%) of them were diagnosed bacteriologically; 65 (80.2%) of them were pulmonary tuberculosis. The most common skin finding was urticaria in 49 (60.5%). The drug responsible for the most common reaction was pyrazinamide. In 49 (60.5%) cases, drugs were given by desensitization and it was successful. The duration of treatment was 7.91 ± 2.5 months (6-18 months). When evaluated in terms of treatment results, 68 (84%) patients successfully completed the treatment.Conclusion: Our study is the largest series of patients in which the demographic and clinical characteristics of type 1 IgE-mediated hypersensitivity developed under antituberculosis treatment were examined. An applicable, understandable and successful diagnostic process roadmap and desensitization scheme that can be used in this situation are presented.